Skip to main content

Kazia Therapeutics Limited (KZIA)

NASDAQ: KZIA · IEX Real-Time Price · USD
8.02
-0.11 (-1.35%)
At close: Dec 8, 2021 4:00 PM
8.21
0.19 (2.37%)
After-hours:Dec 8, 2021 4:26 PM EST
Market Cap108.29M
Revenue (ttm)11.45M
Net Income (ttm)-6.33M
Shares Out13.50M
EPS (ttm)-1.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,134
Open8.20
Previous Close8.13
Day's Range7.91 - 8.38
52-Week Range7.70 - 14.89
Beta2.70
AnalystsBuy
Price Target17.19 (+114.4%)
Earnings Daten/a

About KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based i...

IndustryBiotechnology
IPO DateJan 6, 1999
Employees2,021
Stock ExchangeNASDAQ
Ticker SymbolKZIA
Full Company Profile

Financial Performance

Financial numbers in millions AUDFinancial Statements

Analyst Forecast

According to one analyst, the rating for KZIA stock is "Buy" and the 12-month stock price forecast is 17.19.

Price Target
$17.19
(114.36% upside)
Analyst Consensus: Buy

News

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinica...

4 days ago - PRNewsWire

Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients

Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with glioblastoma. 60mg once daily was identified as th...

5 days ago - Benzinga

GBM AGILE Opens to Paxalisib in Canada

SYDNEY, Nov. 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in gli...

1 week ago - PRNewsWire

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chi...

3 weeks ago - PRNewsWire

PNOC Study in Childhood Brain Cancer Enrols First Patient

SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug p...

3 weeks ago - PRNewsWire

Kazia Enrols First Patient to EVT801 Phase I Clinical Trial

SYDNEY, Nov. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase ...

1 month ago - PRNewsWire

Kazia Therapeutics to Present at LD Micro Main Event

SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenti...

2 months ago - PRNewsWire

Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presen...

2 months ago - PRNewsWire

Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness ...

4 months ago - PRNewsWire

Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs

SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two ...

5 months ago - PRNewsWire

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combinatio...

SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with t...

5 months ago - PRNewsWire

Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigat...

6 months ago - PRNewsWire

Kazia Therapeutics to Present at LD Micro Invitational XI

SYDNEY, June 3, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner, will be presenting virtually ...

6 months ago - PRNewsWire

A Trio of Stocks With Solid Balance Sheets for the Value Investor

Benjamin Graham, the pioneer of value investing, proposed to look for stocks that have a current ratio of more than 2 and more working capital than long-term debt.

Other symbols:CTHRLPTX
7 months ago - GuruFocus

Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis

LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for €1m...

7 months ago - Accesswire

Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed

LONDON, UK / ACCESSWIRE / March 30, 2021 / Kazia (NASDAQ:KZIA) has announced it has signed an agreement for the Greater China rights to paxalisib with Simcere Pharmaceuticals. The deal includes an US$11...

8 months ago - Accesswire

Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater China

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd to develop and commercialize Kazia's investigational new drug, paxalisib, in Greater Ch...

8 months ago - Benzinga

Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cance...

9 months ago - Benzinga

Kazia Therapeutics News: Why KZIA Stock Is Rocketing 43% Higher Today

Kazia Therapeutics (KZIA) news for Friday includes a designation from the U.S. Food and Drug Administration sending KZIA stock flying high.

1 year ago - InvestorPlace